\n

Presentation

\nColitrol injection: Each 1 ml ampoule contains 1 mcg of Calcitriol BP (Vitamin D3). \n \nColitrol capsule: Each capsule contains 0.25 mcg of Calcitriol BP (Vitamin D3). \n \n

\n

Description

\nCalcitriol is one of the most important active metabolites of vitamin D3. It is normally formed in the kidney from its precursor, 25-hydroxycolecalciferol (25-HCC). Physiological daily production is normally 0.5-1.0 mcg and is somewhat higher during periods of increased bone synthesis (e.g. growth or pregnancy). Calcitriol promotes intestinal absorption of Calcium and regulates bone mineralization. \n \n

\n

Indications

\nCalcitriol is indicated for the correction of the abnormalities of Calcium and Phosphate metabolism in patients with renal osteodystrophy. \n \nCalcitriol is also indicated for the treatment of established post-menopausal osteoporosis, hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, vitamin D dependent rickets. \n \n

\n

Dosage & Administration

\nInjection \nThe recommended intravenous initial dose of Calcitriol injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals. \nCapsule \nAdult \nRenal osteodystrophy: The initial daily dose is 0.25 mcg of Calcitriol. In patients with normal or only slighty reduced Calcium level, doses of 0.25 mcg every other day are sufficient. If no satisfactory response in the biochemical parameters and clinical manifestations of the disease is observed within 2-4 weeks, the daily dosage may be increased by 0.25 mcg at 2-4 week intervals. \n \nPost-menopausal osteoporosis: The recommended dose of Calcitriol is 0.25 mcg twice daily. \nSerum calcium and creatinin levels should be determined at 1-3 and 6 months and at 6 monthly intervals thereafter. \nHypoparathyroidism & Rickets: The recommended initial dose of Calcitriol is 0.25 mcg per day in the morning. In patients with renal osteodystrophy or hypoparathyroidism and rickets if within 2-4 weeks no satisfactory response is observed by usual dose then dose may be increased at two to four week intervals. \nElderly patients \nNo specific dosage modifications are required in elderly patents. \nChildren \nDosage in children has not been established. \n \n

\n

Side Effects

\nSince Calcitriol exerts vitamin D activity, adverse effects may occur which are similar to those found when an excessive dose of vitamin D is taken, i.e. hypercalcaemia syndrome or calcium intoxication (depending on the severity and duration of hypercalcaemia). Occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation. \n \n

\n

Precautions

\nImmobilised patients, e.g. those who have undergone surgery, are particularly exposed to the risk of hypercalcaemia. Patients with normal renal function who are taking Calcitriol should avoid dehydration. Adequate fluid intake should be maintained. \n \n

\n

Use in Pregnancy & Lactation

\nPregnancy category C. Calcitriol has been found to be teratogenic in rabbits. There are no adequate and well-controlled studies in pregnant women. Calcitriol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. \n \n

\n

Drug Interaction

\nConcomitant treatment with a thiazide diuretic increases the risk of hypercalcaemia. Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcaemia in such patients may precipitate cardiac arrhythmias. Administration of enzyme inducers such as phenytoin or phenobarbital may lead to increased metabolism and hence reduced serum concentrations of Calcitriol. Therefore higher doses of Calcitriol may be necessary if these drugs are administered simultaneously. Colestyramine can reduce intestinal absorption of fat-soluble vitamins and therefore may impair intestinal absorption of Calcitriol. \n \n

\n

Over Dose

\nAdministration of Calcitriol to patients in excess of their daily requirements can cause hypercalcaemia, hypercalciuria and hyperphospatemia. Since Calcitriol is a derivative of vitamin D, the signs and symptoms of overdose are the same as for an overdose of vitamin D. \n \n

\n

Commercial Pack

\nColitrol injection: Each commercial box contains 1 ampoule of 1 ml solution. \nColitrol capsule: Each commercial box contains 3 blister strips of 10 capsules. \n \n